A recent study aimed to examine whether an early palliative care telehealth intervention results in a better quality of life over usual care for patients with heart failure.
It is the first sodium-glucose co-transporter 2 inhibitor to be approved to treat adults with New York Heart Association’s functional class II-IV heart failure with reduced ejection fraction.
Based on its oral bioavailability and half-life, torsemide may appear to be a more efficient diuretic than furosemide, but authors of a new study wanted to shed more light on the medications’ clinical...
Authors of a new study presented at the AHA Scientific Sessions 2019 sought to determine whether cardiac biomarkers could identify patients at higher baseline risk for cardiovascular mortality or heart...
Researchers analyzed the rates of hospitalizations and rehospitalizations for heart failure among more than 3700 participants with chronic kidney disease and also evaluated the impact of hospitalizations on...
The number of individuals with both diabetes and heart failure is expected to increase. To outline management approaches and the need for future research in treating the conditions, the American Heart...
Because few treatments can successfully improve the clinical status in patients with HFpEF, authors of a study presented at the American Physiological Society’s annual meeting evaluated whether antioxidants...
Researchers analyzed findings of the multi-site MESA Study to determine whether FGF23 is associated with an increased risk for heart failure among individuals with hypertension.
The association between alcohol consumption and survival of older adults who have been newly diagnosed with heart failure is unknown. New research explores this association.
